Regenerative Medical Technology Group (RMTG) fair value: what the stock is really worth
As of Oct 5, 2026: fair value of Regenerative Medical Technology Group $0.06, price $0.05, upside +18.9%, quality 34 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range $0.0072 – $0.3400 · fair‑value band $0.0517 – $0.0740 · the $0.0525 price screens below the $0.0624 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow Regenerative Medical Technology in your weekly email
Every Wednesday you see whether Regenerative Medical Technology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of stem cell therapies.
Show more
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of stem cell therapies. The company is also involved in the treatment of patients; provision of training and seminars; and resale of kits, products, equipment, and services. In addition, it offers reoccurring application of its process using its kits and solutions. Further, it provides solutions from clinical research with the manufacturing and commercialization of viable cell therapy and immune support related products. The company was formerly known as Meso Numismatics, Inc. and changed its name to Regenerative Medical Technology Group Inc. in May 2024. Regenerative Medical Technology Group Inc. was incorporated in 1999 and is based in Boca Raton, Florida.
Stock analysis
Regenerative Medical Technology Group (RMTG) currently trades at $0.0525, while our model-based Fair Value estimate is $0.0624, implying the stock looks roughly 15.9% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $0.0517 (bear) to $0.0740 (bull), the price of $0.0525 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Regenerative Medical Technology Group reported revenue of $5.1M in FY2025 versus $438K in FY2021, a compound +84.7%/yr. Reported net income was −$7.8M in FY2025.
Key figures
Market cap $823K · P/S ratio 0.09 · EPS (TTM) $−0.6800 · Net margin −93.7% · Return on assets (EBIT) −32.7% · Operating margin 14.7% · Revenue (TTM) $9.4M · Revenue growth (YoY) +309%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 56% below its 52-week high and 178% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 19%, RMTG screens cheaper than that median.
Fair Value models
Bear $0.0517Fair Value $0.0624Bull $0.0740
Price $0.0525 · Upside +18.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+24.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+49.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+147.4%
Start year 2020 (pandemic). Over 10 years: +98.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+98.3%
’15
’17
’18
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−814.1% (2020) → −17.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Regenerative Medical Technology Group with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 607 stocks
Beats the industry median on 6/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score34 · Below median
Fair Value upside+18.9% · Top 25%
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets1.6% · Above median
Net margin (TTM)−93.7% · Bottom 25%
Operating margin (TTM)14.7% · Above median
Growth and dividend
Revenue growth309.1% · Top 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM)0.09× · Cheapest 25%
EV/EBITDA3.8× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)59· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 22
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Regenerative Medical Technology Group Fair Value". https://www.fairvalue-calculator.com/stock/RMTG
Frequently asked questions
Is Regenerative Medical Technology Group (RMTG) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $0.0624 versus a price of $0.0525, about +19% upside (undervalued).
What is the fair value of RMTG?
Our model-based fair value for Regenerative Medical Technology Group is $0.0624 (as of Oct 3, 2026), built from audited fundamentals. The current price: $0.0525.
What is the quality score of RMTG?
Regenerative Medical Technology Group has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Regenerative Medical Technology Group (RMTG)?
Our model-based price target is the fair value of $0.0624 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario $0.0517, optimistic scenario $0.0740. It is a calculation from audited fundamentals, not an analyst target.
What is the Regenerative Medical Technology Group stock forecast for 2026?
Our models put fair value at $0.0624, about +19% upside versus a price of $0.0525 (undervalued). Cautious scenario $0.0517, optimistic scenario $0.0740. The calculation is refreshed regularly with new filings.
What is the revenue of Regenerative Medical Technology Group (RMTG)?
Regenerative Medical Technology Group reported trailing-twelve-month revenue of about $9.4M (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Regenerative Medical Technology Group (RMTG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Regenerative Medical Technology Group it is $0.0624 per share (as of Oct 3, 2026), against a price of $0.0525. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Regenerative Medical Technology Group stock overvalued or undervalued in 2026?
As of Oct 3, 2026, RMTG trades below its calculated fair value: price $0.0525, fair value $0.0624, a gap of about +19% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RMTG?
No. The price is what the market pays today ($0.0525); the fair value is what the company's own numbers justify ($0.0624). For Regenerative Medical Technology Group the two are $0.0099 per share apart. That gap is exactly why we show both numbers side by side.
How much is Regenerative Medical Technology Group worth?
The market values Regenerative Medical Technology Group at about $823K (market capitalisation, as of Oct 3, 2026). Per share that is $0.0525; our models calculate a fair value of $0.0624 per share.
What do the bullish and bearish scenarios say about RMTG?
Our models span a range for Regenerative Medical Technology Group: cautious scenario $0.0517, base $0.0624, optimistic $0.0740 per share (as of Oct 3, 2026, price $0.0525). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Regenerative Medical Technology Group (RMTG)?
Balance-sheet figures for Regenerative Medical Technology Group (as of Oct 3, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is RMTG from its 52-week high?
Regenerative Medical Technology Group trades at $0.0525, about 56% below its 52-week high of $0.1200 and 178% above the low of $0.0189 (as of Oct 5, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0624 is for.
Which stocks are comparable to Regenerative Medical Technology Group?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Regenerative Medical Technology Group stock attractive at the current price?
The data as of Oct 3, 2026: price $0.0525, calculated fair value $0.0624 (+19%), Quality Score 34/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RMTG calculated?
We run Regenerative Medical Technology Group through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0624, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Regenerative Medical Technology Group currently trades 16 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Regenerative Medical Technology Group (RMTG)?
The closing price on Oct 5, 2026 was $0.0525. Our model-based fair value is $0.0624, about +19% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Regenerative Medical Technology Group right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Regenerative Medical Technology Group
How large is the market capitalisation of Regenerative Medical Technology Group (RMTG)?
The market capitalisation of Regenerative Medical Technology Group is $823K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Regenerative Medical Technology Group (RMTG)?
The price-to-sales ratio of Regenerative Medical Technology Group is 0.09 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Regenerative Medical Technology Group (RMTG)?
Earnings per share at Regenerative Medical Technology Group are $−0.6800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Regenerative Medical Technology Group (RMTG)?
The net margin of Regenerative Medical Technology Group is −93.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Regenerative Medical Technology Group (RMTG)?
On an EBIT basis the return on assets of Regenerative Medical Technology Group is −32.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Regenerative Medical Technology Group (RMTG)?
The operating margin of Regenerative Medical Technology Group is 14.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Regenerative Medical Technology Group (RMTG)?
Revenue at Regenerative Medical Technology Group is growing +309% versus a year earlier (3y avg +49.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Regenerative Medical Technology Group (RMTG) generate?
The free cash flow of Regenerative Medical Technology Group is −$1.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Regenerative Medical Technology Group (RMTG) carry?
The net debt of Regenerative Medical Technology Group is $18.6M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Regenerative Medical Technology Group in the live analysis
One click puts Regenerative Medical Technology Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Oct 3, 2026